The company manufactures and sells thermoformed plastic packaging products, such as disposable cups and containers, primarily for the food and beverage industry.
The company operates in a highly fragmented, low-barrier commodity plastic packaging market, evidenced by extremely low and volatile net margins (2.2%) and poor returns on capital (1.9%). There is no evidence of brand power or cost advantage, as revenue growth has not translated into earnings, which have significantly declined over the period.
Management has deployed capital into low-yielding fixed assets and significant inter-corporate advances to related parties rather than returning value to shareholders. The negative cash conversion and declining EPS suggest that reinvestment is not generating incremental value.
The business collapsed as the thin interest coverage of 1.3 finally buckled under rising costs, while the capital previously siphoned into related-party advances proved unrecoverable. Despite growing the top line, the company continued to incinerate cash through a negative conversion cycle, effectively funding its own demise by selling commodity products at a loss. The lack of internal controls and frequent management turnover eventually led to a liquidity crisis where the company could no longer service its debt or maintain its aging fixed assets.
RichFakir rates Polymac Thermoformers Ltd's business quality as poor — 13/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Polymac Thermoformers Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Polymac Thermoformers Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Polymac Thermoformers Ltd's fair value is about ₹5 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →